FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHA Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor [NCT06065540]RESEARCHSemaglutide in Alcohol Use Disorder [NCT07949474]RESEARCHEffects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease [NCT06409130]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]NEWS‘Selling and marketing snake oil’: The debate over compounded GLP-1sRESEARCHSemaglutide Effects on Sperm Concentration in Overweight Infertile Men [NCT07946796]RESEARCHTirzepatide for the REduction of AceTazolamide in Idiopathic Intracranial Hypertension [NCT07946315]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHA Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor [NCT06065540]RESEARCHSemaglutide in Alcohol Use Disorder [NCT07949474]RESEARCHEffects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease [NCT06409130]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]NEWS‘Selling and marketing snake oil’: The debate over compounded GLP-1sRESEARCHSemaglutide Effects on Sperm Concentration in Overweight Infertile Men [NCT07946796]RESEARCHTirzepatide for the REduction of AceTazolamide in Idiopathic Intracranial Hypertension [NCT07946315]

Pour des fins de recherche uniquement. Déclaration complète →

Recherche/Highlighting the evolving understanding of GIP and GLP-1 in metabolic diseases and their therapeutic implications.
Retour à la bibliothèque de recherche
GIPGLP-1

Highlighting the evolving understanding of GIP and GLP-1 in metabolic diseases and their therapeutic implications.

May 17, 2026
Share

Papier source

The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update.

Nauck Michael A et al.Diabetes, obesity & metabolism2021
Recherche émergente

Basé sur des recherches émergentes. Ces découvertes sont prometteuses mais nécessitent une validation supplémentaire.

À propos de cette analyse

Cet article décompose les résultats du papier source ci-dessus dans un langage accessible pour la communauté de recherche en peptides. Notre objectif est d'highlighter ce qui compte le plus — les implications pratiques, la force des preuves et ce que cela signifie pour la recherche en cours.

The Dual Role of GIP and GLP-1 in Metabolic Health: A Closer Look

Published: May 17, 2026 | Source: Diabetes, obesity & metabolism (2021) | Category: GIP, GLP-1

Overview

This review paper delves into the roles of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) in metabolic health, focusing on their effects on glucose homeostasis and potential therapeutic benefits for type 2 diabetes and cardiovascular disease. The findings highlight the diminished incretin effect in patients with type 2 diabetes and suggest that co-agonists targeting both GIP and GLP-1 receptors may offer superior efficacy.

Study Background

Incretins, particularly GIP and GLP-1, have been recognized for their critical role in enhancing insulin secretion after meals. Prior research established the importance of these peptides in maintaining normal glucose tolerance through their interaction with pancreatic beta cells. However, the specific mechanisms by which GIP and GLP-1 contribute to metabolic health and potential therapeutic benefits were not fully understood. This review aims to provide a comprehensive update on recent findings regarding these incretins.

What the Research Found

The study reveals that both GIP and GLP-1 play significant roles in glucose homeostasis, with additive effects on insulin secretion. However, their functions diverge when it comes to glucagon regulation: GLP-1 suppresses glucagon release while GIP increases it, both actions being glucose-dependent. Importantly, the review highlights that type 2 diabetic patients exhibit a reduced incretin effect despite normal levels of GIP and GLP-1 secretion. This reduction is more pronounced for GIP than for GLP-1, indicating a loss of acute insulinotropic activity in GIP.

Moreover, beyond their role in glucose regulation, both peptides have additional biological functions. For instance, GLP-1 has been shown to reduce appetite and food intake, potentially leading to long-term weight reduction, although similar effects for GIP are less confirmed in human studies. Additionally, GIP promotes triglyceride storage in white adipose tissue through mechanisms that extend beyond insulin secretion alone.

What This Means for Peptide Users

For individuals using peptides like GLP-1 or considering co-agonists targeting both GIP and GLP-1 receptors, this research underscores the importance of understanding these peptides' multifaceted roles. The diminished incretin effect in type 2 diabetes suggests that therapeutic strategies should consider enhancing the efficacy of both GIP and GLP-1 to achieve better glucose control. Furthermore, the potential for co-agonists targeting both pathways may offer a more comprehensive approach to managing metabolic diseases.

Limitations and Caveats

As a review paper, this study relies heavily on existing literature and does not present new experimental data. Consequently, it may not capture all recent findings or nuances in experimental methodologies. Additionally, the clinical relevance of some findings, such as GIP's role in triglyceride storage, is still under investigation and requires further validation through human studies.

How This Compares to Previous Research

This review builds upon previous research by providing a more detailed analysis of the physiological roles of GIP and GLP-1. It aligns with earlier findings on their insulinotropic effects but offers new insights into their divergent actions on glucagon secretion and additional biological functions. The emphasis on the reduced incretin effect in type 2 diabetes is consistent with previous studies, reinforcing the need for targeted therapeutic approaches.

Our Analysis

PeptideVault views this review as a valuable update to our understanding of GIP and GLP-1's roles in metabolic health. While it synthesizes existing knowledge effectively, the reliance on previously published data means that some aspects may require further investigation through new experimental studies. The implications for peptide therapy are promising but should be interpreted with caution due to ongoing research needs.

Key Takeaways

  • Diminished Incretin Effect: Type 2 diabetic patients exhibit a reduced incretin effect, particularly in GIP.
  • Therapeutic Potential: Co-agonists targeting both GIP and GLP-1 receptors may offer superior efficacy for metabolic disease management.
  • Further Research Needed: Additional studies are required to fully understand the clinical implications of GIP's role in triglyceride storage and other biological functions.

Original Source

Citation: Nauck Michael A, Quast Daniel R, Wefers Jakob et al. (2021). The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update.. Diabetes, obesity & metabolism. DOI: 10.1111/dom.14496

Access:

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

Note de l'éditeur

Cette analyse a été préparée par l'équipe de recherche de Peptide Contacts. Nous encourageons les lecteurs à vérifier les informations auprès du papier source complet pour la méthodologie et les données complètes. L'original de la publication est disponible sur le PubMed.

Recherches connexes

Comments

Sign in to join the discussion

Cette analyse est générée à partir d'une recherche peer-reviewed pour des fins éducatives uniquement. Elle ne constitue pas un avis médical. Consultez toujours un fournisseur de soins de santé qualifié avant d'utiliser tout traitement basé sur les peptides.